Scarica l'app Stockscreener
1.99
1.02%
0.02
Pre-mercato:
2.00
0.01
+0.50%
Precedente Chiudi:
$1.97
Aprire:
$2.02
Volume 24 ore:
356.62K
Relative Volume:
0.24
Capitalizzazione di mercato:
$112.39M
Reddito:
-
Utile/perdita netta:
$-29.29M
Rapporto P/E:
-3.0648
EPS:
-0.6493
Flusso di cassa netto:
$-24.74M
1 W Prestazione:
+5.85%
1M Prestazione:
+18.45%
6M Prestazione:
-18.78%
1 anno Prestazione:
-45.33%
Intervallo 1D:
$1.915
$2.05
Intervallo di 1 settimana:
$1.75
$2.145
Portata 52W:
$0.41
$4.44
Tuhura Biosciences Inc Stock (HURA) Company Profile
Nome
Tuhura Biosciences Inc
Settore
Industria
Telefono
813-875-6600
Indirizzo
10500 UNIVERSITY CENTER DR., TAMPA
Compare HURA vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HURA
Tuhura Biosciences Inc
|
1.99 | 112.39M | 0 | -29.29M | -24.74M | -0.6493 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Tuhura Biosciences Inc Stock (HURA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-03 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-19 | Iniziato | Rodman & Renshaw | Buy |
| 2024-11-05 | Iniziato | Maxim Group | Buy |
Tuhura Biosciences Inc Borsa (HURA) Ultime notizie
TuHURA R&D Jumps 75% in Q2 - AOL.com
TuHURA Biosciences appoints Craig Tendler as chief medical officer By Investing.com - Investing.com Australia
TuHURA Biosciences, Inc.Common Stock (NQ: HURA - The Chronicle-Journal
Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers - ChartMill
TuHURA Biosciences (NASDAQ:HURA) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Growth Report: How is TuHURA Biosciences Inc managing supply chain issuesWeekly Earnings Recap & Consistent Growth Equity Picks - baoquankhu1.vn
TuHURA Biosciences, Inc. Common Stock (HURA) Stock Price Today & Analysis - Gotrade
HURA Earnings History & Surprises | EPS & Revenue Results | TUHURA BIOSCIENCES INC (NASDAQ:HURA) - ChartMill
TuHURA Biosciences (HURA) Expected to Release Quarterly Earnings on Thursday - MarketBeat
Bull Bear: Is TuHURA Biosciences Inc a strong candidate for buy and hold2026 Earnings Surprises & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Moving Averages: Is TuHURA Biosciences Inc attractive for institutional investorsPortfolio Growth Summary & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
TuHURA Biosciences (NASDAQ:HURA) Trading Down 3.1%Here's Why - MarketBeat
Wall Street Zen Upgrades TuHURA Biosciences (NASDAQ:HURA) to "Hold" - MarketBeat
Market Rankings: What dividend growth rate does TuHURA Biosciences Inc offerTrade Entry Report & Community Trade Idea Sharing Platform - baoquankhu1.vn
HURA Should I Buy - Intellectia AI
Aug PostEarnings: Will TuHURA Biosciences Inc outperform its industry peersPortfolio Gains Report & Capital Efficiency Focused Ideas - baoquankhu1.vn
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
HURA Technical Analysis & ETF Price Forecast - Intellectia AI
TuHURA Biosciences stock gains after Nasdaq compliance - Investing.com India
Update Recap: How is TuHURA Biosciences Inc managing supply chain issuesJuly 2025 Highlights & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
TuHURA Biosciences stock gains after Nasdaq compliance By Investing.com - Investing.com South Africa
TuHURA Biosciences regains Nasdaq listing compliance - Investing.com
Cancer immunotherapy firm TuHURA keeps share price over $1 to satisfy Nasdaq - Stock Titan
Critical Review: Fate Therapeutics (NASDAQ:FATE) vs. TuHURA Biosciences (NASDAQ:HURA) - Defense World
TuHURA Biosciences Announces Participation in Upcoming Investor Conferences - Nasdaq
HURA.O Technical Analysis & Stock Price Forecast - Intellectia AI
Cancer immunotherapy developer TuHURA plans back-to-back investor events in March - Stock Titan
TuHURA Biosciences (HURA) to Release Earnings on Wednesday - MarketBeat
TuHura files IND for leukemia drug combination study By Investing.com - Investing.com India
TuHura files IND for leukemia drug combination study - Investing.com Australia
Tuhura Files Investigational New Drug Application for Tbs-2025 in the Treatment of Blood-Related Cancers - marketscreener.com
New TuHURA antibody aims to boost leukemia drug response - Stock Titan
Is TuHURA Biosciences Inc. a strong growth stockJuly 2025 Technicals & Technical Entry and Exit Tips - mfd.ru
HURA PE Ratio & Valuation, Is HURA Overvalued - Intellectia AI
Should I trade or invest in TuHURA Biosciences Inc.2025 Earnings Impact & Free Community Consensus Stock Picks - mfd.ru
Will TuHURA Biosciences Inc. (PL3) stock sustain bullish trend into 2025 - mfd.ru
TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - The Malaysian Reserve
Will TuHURA Biosciences Inc. stock maintain dividend yieldWeekly Trend Recap & Risk Managed Investment Signals - mfd.ru
HURA Stock Strongly Rises on Early Morning Surge - timothysykes.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Is TuHURA Biosciences Inc. stock cheap at current valuationWeekly Trend Summary & Breakout Confirmation Alerts - mfd.ru
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Market Review: How volatile is Draganfly Inc stockTrade Risk Assessment & Smart Swing Trading Alerts - baoquankhu1.vn
FDA Grants Orphan Drug Status to Experimental Melanoma Therapy After Phase 1 Results - streetwisereports.com
HURA Stock Sparks 7,000% Surge In Retail Chatter After FDA Orphan Drug Win For Melanoma Therapy - Stocktwits
TuHURA Biosciences receives FDA orphan drug designation for melanoma drug By Investing.com - Investing.com South Africa
TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma - MEXC
TuHURA Receives FDA Orphan Drug Designation - Intellectia AI
TuHURA Biosciences receives FDA orphan drug designation for melanoma drug - Investing.com
FDA Grants Orphan Drug Status to IFx-2.0 for Advanced Melanoma Care - Cure Today
Tuhura Biosciences Inc Azioni (HURA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):